Why is it hard to terminate failing projects in pharmaceutical R&D?

Nature Reviews Drug Discovery

Volumn 14, Issue 10, 2015, Pages 663-664

  Peck, Richard W ^a   Lendrem, Dennis W ^b   Grant, Iain ^c   Lendrem, B Clare ^b   Isaacs, John D ^b  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c Phruitful Consulting   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

BEHAVIOR; CAREER MOBILITY; COGNITIVE BIAS; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG DETERMINATION; DRUG DEVELOPMENT; DRUG EFFECT; DRUG INDUSTRY; DRUG MARKETING; DRUG QUALITY; DRUG RESEARCH; METHODOLOGY; NOTE; PERSONNEL MANAGEMENT; PHARMACEUTICAL RESEARCH AND DEVELOPMENT TERMINATION; PRIORITY JOURNAL; PRODUCTIVITY; RESOURCE MANAGEMENT; SCIENTIST; TOTAL QUALITY MANAGEMENT; HUMAN; RESEARCH;

DRUG DISCOVERY; DRUG INDUSTRY; HUMANS; RESEARCH;

EID: 84942989227     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4725     Document Type: Note

References (5)

1. Paul, S. M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
2. Owens, P. K. et al. A decade of innovation in pharmaceutical R&D: the Chorus model. Nat. Rev. Drug Discov. 14, 17-28 (2015).
3. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431 (2014).
4. Lendrem, D. W. et al. Progression-seeking bias and rational optimism in research and development. Nat. Rev. Drug Discov. 14, 219-221 (2015).
5. Peck, R. W. Driving earlier clinical attrition: if you want to find the needle, burn down the haystack. Considerations for biomarker development. Drug Discov. Today 12, 289-294 (2007).